View Older Stories View More Recent Stories

Feb 10, 2021 04:47PM Seagen (SGEN), Genmab (GMAB) Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Feb 10, 2021 04:05PM Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Feb 10, 2021 04:05PM Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Feb 10, 2021 04:05PM Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Oct 30, 2020 07:17AM Genmab A/S (GMAB), ADC Therapeutics (ADCT) Announce Amended Agreement for Camidanlumab Tesirine
Oct 30, 2020 07:15AM Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
Oct 30, 2020 07:15AM Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami)
Sep 21, 2020 10:20AM Seattle Genetics (SGEN) and Genmab (GMAB) Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO
Sep 21, 2020 10:20AM Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Sep 21, 2020 10:20AM Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Sep 21, 2020 10:20AM Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Jun 29, 2020 04:31PM Seattle Genetics (SGEN) Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Jun 10, 2020 06:04AM Genmab (GMAB) and AbbVie (ABBV) Announce Broad Oncology Collaboration, Genmab to Receive Upfront Payment of $750M With Total Potential Milestones of Up to $3.15B
Jun 10, 2020 06:00AM Genmab and AbbVie Announce Broad Oncology Collaboration
Jun 10, 2020 06:00AM AbbVie and Genmab Announce Broad Oncology Collaboration
Jun 10, 2020 06:00AM Genmab and AbbVie Announce Broad Oncology Collaboration
Dec 19, 2019 11:05AM Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
Dec 19, 2019 11:05AM Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
Dec 19, 2019 10:20AM Genmab A/S (GMAB), CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
Dec 19, 2019 10:19AM Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
Dec 19, 2019 10:19AM Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
View More Recent Stories View Older Stories